Clinical trial
A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT07136142 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 23, 2025
- Completion date
- February 28, 2027
- Enrollment
- 150 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
malignant solid tumor